STUDY OBJECTIVES: To analyze cyclic alternating pattern (CAP) in restless legs syndrome (RLS) and the eventual changes induced by the acute administration of pramipexole. SETTING: Sleep clinic in a scientific research institute. INTERVENTIONS:Placebo or pramipexole 0.25 mg. METHODS:Thirty-four patients were included: 19 patients received 0.25 mg ofpramipexole and 15 were given placebo. The control group included 13 normal subjects. Nocturnal polysomnography was carried out in all subjects, and a second night was recorded after pramipexole or placebo was administered to patients with RLS. Sleep stages, CAP, and leg movement activity were scored following standard criteria. MEASUREMENTS AND RESULTS: At baseline, rapid eye movement sleep latency was significantly longer in patients with RLS than in normal control subjects, and the periodic leg movement during sleep index (PLMS) was also significantly higher. On the contrary, many CAP parameters appeared to be significantly different, with a general increase in CAP rate in patients with RLS. Acute administration of pramipexole induced moderate changes in sleep architecture (increased number of stage shifts/h, sleep efficiency, and percentage of stage 2 sleep; decreased wakefulness after sleep onset; and a lower PLMS index. No effects of treatment on CAP were observed. CONCLUSION:Patients with RLS show significant abnormalities in sleep microstructure, represented by an excessive sleep instability/discontinuity. Acute pramipexole administration seems to exert no action on these abnormalities; the moderate effects seen on sleep architecture might be interpreted as the beneficial consequence of the removal of presleep RLS symptoms and PLMS.
RCT Entities:
STUDY OBJECTIVES: To analyze cyclic alternating pattern (CAP) in restless legs syndrome (RLS) and the eventual changes induced by the acute administration of pramipexole. SETTING: Sleep clinic in a scientific research institute. INTERVENTIONS: Placebo or pramipexole 0.25 mg. METHODS: Thirty-four patients were included: 19 patients received 0.25 mg of pramipexole and 15 were given placebo. The control group included 13 normal subjects. Nocturnal polysomnography was carried out in all subjects, and a second night was recorded after pramipexole or placebo was administered to patients with RLS. Sleep stages, CAP, and leg movement activity were scored following standard criteria. MEASUREMENTS AND RESULTS: At baseline, rapid eye movement sleep latency was significantly longer in patients with RLS than in normal control subjects, and the periodic leg movement during sleep index (PLMS) was also significantly higher. On the contrary, many CAP parameters appeared to be significantly different, with a general increase in CAP rate in patients with RLS. Acute administration of pramipexole induced moderate changes in sleep architecture (increased number of stage shifts/h, sleep efficiency, and percentage of stage 2 sleep; decreased wakefulness after sleep onset; and a lower PLMS index. No effects of treatment on CAP were observed. CONCLUSION:Patients with RLS show significant abnormalities in sleep microstructure, represented by an excessive sleep instability/discontinuity. Acute pramipexole administration seems to exert no action on these abnormalities; the moderate effects seen on sleep architecture might be interpreted as the beneficial consequence of the removal of presleep RLS symptoms and PLMS.
Authors: Marco Zucconi; Raffaele Ferri; Richard Allen; Paul Christian Baier; Oliviero Bruni; Sudhansu Chokroverty; Luigi Ferini-Strambi; Stephany Fulda; Diego Garcia-Borreguero; Wayne A Hening; Max Hirshkowitz; Birgit Högl; Magdolna Hornyak; Martin King; Pasquale Montagna; Liborio Parrino; Giuseppe Plazzi; Mario G Terzano Journal: Sleep Med Date: 2006-02-03 Impact factor: 3.492
Authors: Diego Garcia-Borreguero; Jeffrey Patrick; Sarah DuBrava; Philip M Becker; Alan Lankford; Crystal Chen; Jeffrey Miceli; Lloyd Knapp; Richard P Allen Journal: Sleep Date: 2014-04-01 Impact factor: 5.849